Kristie L. Kahl | Authors

June 13, 2021

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

June 08, 2021

Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.

June 08, 2021

For men with asymptomatic or mildly symptomatic mCRPC, using bone-protecting agents during treatment with radium-223 plus enzalutamide controlled the risk for fractures.

June 04, 2021

Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.

June 04, 2021

The CAR T-cell product idecabtagene vicleucel in patients with heavily pretreated multiple myeloma continued to show benefit of therapy at a median follow-up of 24.8 months.

June 04, 2021

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.

May 27, 2021

Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.

May 27, 2021

A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.

May 26, 2021

A discussion regarding typical response rates to frontline therapy for extensive-stage small cell lung cancer and considerations for incorporating an immunotherapy agent into first-line treatment.

May 26, 2021

An overview of current gaps in treatment for patients with extensive-stage, or metastatic small cell lung cancer.